Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $33,123.12 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 20,964 shares of Invivyd stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the sale, the insider owned 117,717 shares in the company, valued at approximately $185,992.86. This trade represents a 15.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Timothy Edward Lee also recently made the following trade(s):

• On Tuesday, February 17th, Timothy Edward Lee sold 19,663 shares of Invivyd stock. The stock was sold at an average price of $1.54, for a total transaction of $30,281.02.

Invivyd Price Performance

Invivyd stock traded up $0.10 during midday trading on Wednesday, reaching $1.65. The company had a trading volume of 1,468,415 shares, compared to its average volume of 3,015,442. Invivyd, Inc. has a 12-month low of $0.46 and a 12-month high of $3.07. The company has a market capitalization of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60. The firm’s fifty day simple moving average is $2.19 and its 200-day simple moving average is $1.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IVVD. Courier Capital LLC acquired a new stake in Invivyd in the 4th quarter valued at about $25,000. Bronte Capital Management Pty Ltd. acquired a new position in shares of Invivyd during the fourth quarter worth about $27,000. DRW Securities LLC purchased a new stake in shares of Invivyd during the fourth quarter worth approximately $27,000. ProShare Advisors LLC purchased a new stake in shares of Invivyd during the fourth quarter worth approximately $30,000. Finally, State of Wyoming acquired a new stake in Invivyd in the fourth quarter valued at approximately $30,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Multiple Form 4 filings disclose open‑market sales (no new corporate/clinical announcements). The disclosures are routine SEC insider-sale filings rather than earnings or clinical-data releases. Representative SEC Filing
• Neutral Sentiment: Aggregate size and liquidity context — filings show insiders sold a total of over ~220,000 shares across Feb. 17–18 (multiple executives, see items below). Today’s volume (≈1.47M) is below the stock’s 3M average, which can amplify price moves on relatively modest buying or selling flows.
• Negative Sentiment: Jill Andersen — sold 32,771 shares on 2/17 at ~$1.54 and 34,939 shares on 2/18 at ~$1.58; filings show a double‑digit percentage reduction in her holdings. SEC Filing – Jill Andersen
• Negative Sentiment: Timothy Edward Lee — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale reduced his ownership by ~12–15%. SEC Filing – Timothy Lee
• Negative Sentiment: William E. Duke (CFO) — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; filings show ~13–16% reductions in his holdings. SEC Filing – William Duke
• Negative Sentiment: Julie Green — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale trimmed her stake by ~13–16%. SEC Filing – Julie Green
• Negative Sentiment: Robert D. Allen III — sold 18,189 shares on 2/17 at ~$1.54 and 19,392 on 2/18 at ~$1.58; filings show ~12–14% reductions in his holdings. SEC Filing – Robert Allen

Analyst Ratings Changes

IVVD has been the subject of a number of research reports. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. Finally, HC Wainwright upped their price target on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.